| Catalog No. | CB894016 |
|---|
| Species reactivity | Dog |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Caninized |
|---|
| Isotype | IgG2-kappa-lambda |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
CD52 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q28896 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | AT-005, AT005, 1608122-71-9 |
|---|
| Background | Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.
• CD52 antigen--a review., PMID:11257744
• Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era., PMID:34268256
• CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma., PMID:37975535
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)., PMID:29447988
• Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors., PMID:38242120
• The immunological function of CD52 and its targeting in organ transplantation., PMID:28283679
• CD52 (CAMPATH1)., PMID:11860230
• Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation., PMID:39281063
• CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma., PMID:36587029
• CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation., PMID:33731828
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
